Brief: PCI Biotech completes dose escalation in study with fimaporfin

PCI Biotech Holding ASA

22/01/2016 06:58

Jan 22 (Reuters) - PCI Biotech Holding ASA  PCIB.OL : 
    * Dose escalation in the bile duct cancer study with fimaporfin completed with promising 
early signs of efficacy 
    * Cohort Review Committee (CRC) of clinical experts and company representatives recommended 
that study progress into phase II 
    * CRCs recommendation is based on early promising signs of tumour response in last dose 
cohorts, combined with experience from earlier clinical studies with fimaporfin 
 
Source text for Eikon:  ID:nDjc5STkr  
Further company coverage:  PCIB.OL  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))